Aging is a natural process that all living beings experience. In humans, it is characterized by physical changes such as wrinkles, thinning hair, and decreased muscle mass. While most people view aging as a normal part of life, some may experience an aging disorder. An aging disorder, also known as a progeroid syndrome, is a group of rare genetic diseases that cause accelerated aging from birth. These diseases are typically caused by mutations in certain genes, and involve the loss of functionality in organs and systems throughout the body. Many symptoms of aging disorders are similar to those caused by normal aging; however, individuals with progeroid syndromes tend to experience these symptoms to a greater degree at a much earlier stage. Although each type of progeroid syndrome has its own unique set of symptoms, some of the most common include growth delay, a disproportionate body shape, vision problems, physical and mental developmental disabilities, early onset of wrinkling and skin loosening, and a shortened lifespan. Due to their rarity, there is currently no known cure for aging disorders. However, many treatments can help individuals manage some of the symptoms. These treatments may include physical therapy, gene therapy, dietary modifications, and psychological support. Additionally, medical research has advanced significantly in recent years and may lead to new treatments in the future. In conclusion, aging disorders are a group of rare genetic diseases that result in accelerated aging. While there is no cure, treatments are available that can help individuals manage some of the symptoms. With the help of medical advances, researchers hope to develop more effective treatments in the future.
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : Beyond plaques: 10-nanometer-scale pathoconnectomics of Alzheimer’s disease
Ons M Saad, Panluminate Inc., United States
Title : Results from the global phase 3 trial (IB1001-303) evaluating levacetylleucine in children and adults with ataxia-telangiectasia
Chidinma Ejim, IntraBio, United States
Title : A phase 3, multinational, randomized, placebo-controlled, double-blind, crossover trial (IB1001-304) evaluating levacetylleucine in CACNA1A
Chidinma Ejim, IntraBio, United States
Title : Clinical and molecular phenotype of PTRHD1-associated juvenile parkinsonism
Bhavan A Modi, Barrow Neurological Institute at Phoenix Children's, United States